Should Left Ventricular Assist Device Should Be Standard of Care for Patients With Refractory Heart Failure Who Are Not Transplantation Candidates?

**Left Ventricular Assist Devices Should Be Considered Standard of Care for Patients With Refractory Heart Failure Who Are Not Transplantation Candidates**

Mandeep R. Mehra, MD; Michael J. Domanski, MD

The development of current mechanical circulatory support (MCS) systems began in the 1960s as an effort to provide a therapeutic option for patients with refractory advanced heart failure.1 Today, MCS represents a viable alternative to cardiac transplantation for the overwhelming majority of patients in whom age, comorbidities, or the profound shortage of donors makes transplantation infeasible.

Response by Owens and Jessup on p 3087

Painstaking work on the technique of orthotopic cardiac transplantation, coupled with advances in the knowledge of immunology, resulted in the improvements in survival and quality of life that make cardiac transplantation the treatment of choice for individuals with advanced heart failure. MCS has only recently become accepted for widespread clinical use.2 Early MCS designs were based on the assumption that maintaining pulsatility of flow was a physiological necessity. These bulky devices were of limited durability and resulted in a great deal of morbidity in the form of hemotologic, neurological, and infectious complications.3 Current (second- and third-generation) devices deliver continuous flow (either axial [HeartMate II] or centrifugal [Heartware HVAD]) and have far fewer moving parts (only a rotor); as a result, they are smaller, quieter, and far more durable (estimated to last ≥10 years compared with 18 months) than the early pulsatile systems.4 Although no longer in common use, early pulsatile-flow left ventricular assist devices (LVADs) provided the first proof of principle that MCS can extend life of well-selected patients with advanced heart failure refractory to traditional optimal medical therapy. The development of continuous-flow devices has made MCS a practical clinical tool, and outcomes with the newer devices provide a convincing rationale for LVADs as standard of care in well-selected patients with refractory heart failure in whom transplantation is not an option.

Advent of LVAD Therapy in Transplantation-Ineligible Advanced Heart Failure

Proof of Principle

Recognition that LVADs intended as a bridge to cardiac transplantation delivered durable support to some patients who were not transplanted provided rationale for the Ran-
domized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) Trial. This study, reported in 2001, was performed to determine whether MCS with a first-generation pulsatile LVAD could improve survival of end-stage heart failure patients compared with medical therapy.

REMATCH enrolled patients who were not candidates for transplantation who were in New York Heart Association functional class IV heart failure for at least 90 days despite standard medical therapy, had a left ventricular ejection fraction \( \leq 0.25 \), had peak oxygen consumption \( (\text{PVO}_2) \leq 12 \text{ mL \cdot kg}^{-1} \cdot \text{min}^{-1} \), or had a clinical picture including symptomatic hypotension, deteriorating renal function, or worsening pulmonary congestion. Later, the entry criteria were broadened to include \( \text{PVO}_2 \leq 14 \text{ mL \cdot kg}^{-1} \cdot \text{min}^{-1} \) and patients in New York Heart Association class IIIb or IV requiring intra-aortic balloon pump or inotropic support. Patients were randomized to either LVAD implantation or optimal medical therapy. A total of 129 patients were randomized. The 1-year survival was 52% in the LVAD group compared with 23% in the medically treated patients \((P=0.002)\); the 2-year survival was 28% in the LVAD group and 8% in the medically treated patients. There was also improvement in quality of life in the LVAD patients compared with the medically treated patients. This trial was conducted with a first-generation LVAD that would now be regarded as obsolete, but the study derives its fundamental importance from being a proof of the principle that MCS can improve the survival of late-stage heart failure patients who had an expected 75% 1-year mortality rate. The REMATCH trial was not followed by widespread clinical use of pulsatile LVADs because nearly all of the patients with the LVAD died within 2 years, there was extensive associated morbidity, and the median survival improvement was only 8 months, of which as many as 3 months were in the hospital.

Progress in LVAD Technology

A major advancement in MCS technology occurred with the introduction of the currently used continuous-flow LVADs that are small-profile pumps that continuously draw blood from the left ventricle and then propel it back to the aorta in a nonpulsatile manner. These devices are simpler, quieter, smaller, and more durable than the first-generation pulsatile-flow device used in REMATCH. The Thoratec HeartMate II was the first of these devices to be tested in a large randomized trial against the older-generation device used in REMATCH that achieved regulatory approval. To meet entry criteria, Slaughter and colleagues\(^6\) enrolled transplantation-ineligible patients with a left ventricular ejection fraction <25\%, \( \text{PVO}_2 < 14 \text{ mL \cdot kg}^{-1} \cdot \text{min}^{-1} \) or <50% of predicted, New York Heart Association function class IIIb or IV symptoms for at least 45 of the 60 days before enrollment, or intra-aortic balloon pump dependence for a period of 7 days or on inotropes for at least 14 days before enrollment. A total of 200 patients were randomly assigned in a 2:1 ratio to a continuous-flow LVAD or a pulsatile-flow LVAD. The primary end point of the study was the composite of 2-year survival free of stroke and reoperation to replace the device. Quality of life was also assessed. The mean left ventricular ejection fraction was 0.17, and close to 80% of the patients were on intravenous inotropes at entry; >20% were on an intra-aortic balloon pump. In this study, 46% of patients in the continuous-flow second-generation LVAD group and only 11% of the pulsatile-flow first-generation LVAD group reached the primary end point \((P<0.001)\). The quality of life improved significantly from baseline in both groups. In addition, there was a 38% reduction in the number of hospitalizations in the continuous-flow patients compared with the pulsatile device patients. Interestingly, the survival curve of the older first-generation pulsatile LVAD group was unchanged from that reported in the REMATCH trial. That survival with medical therapy alone for late-stage heart failure patients may not have changed substantially since 2001 is supported by the Investigation of Nontransplant-Eligible Patients Who Are Inotrope Dependent (INTrEPID) study, reported in 2007.\(^7\) This observational study examined a group of noncandidates for transplantation who could not be weaned from inotropic therapy and were offered an LVAD. Eighteen were not implanted because of either patient refusal or unavailability of the LVAD. The important point here is that the medical group survival (no LVAD) is extremely poor and comparable to that of the medical treatment group in REMATCH.

Real-World Outcomes and Trends

The Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS), a National Heart Lung and Blood Institute–sponsored collaborative database, analyzes US Food and Drug Administration–approved durable MCS device implantations in the United States.\(^8\) This database now includes >4000 MCS implantations from June 23, 2006, through June 30, 2011. MCS centers in the United States designated by the Centers for Medicare and Medicaid Services as destination therapy (DT) centers are required to enter all implantations for durable devices into the INTERMACS database. The third INTERMACS report focused specifically on DT patients, and the recently published fourth report updated these analyses.\(^9\) The INTERMACS registry classifies patients as DT if they have no option to recover end-organ function and will likely remain transplantation ineligible. The third INTERMACS report in 2011 outlined outcomes for 385 DT patients and reported that advanced age, renal dysfunction, and a high body mass index were the principal reasons for this classification.\(^9\) Available longer-term follow-up of DT patients was mostly for those who received the first-generation device and demonstrated a disappointing 61% and 39% survival at 1 and 2 years, respec-
tively. However, for the continuous-flow device group, the 1-year survival was already approaching 75%, indicating the marked benefit of the newer technology. The more recent fourth INTERMACS report described a marked increase in device placement as DT. In the 4 years including 2006 to 2009, 135 DT devices were placed; 464 were placed in 2010; and 248 DT devices were placed in the first 6 months of 2011. This DT indication proportionally represents 34% of all devices placed in the United States from January to June 2011. The results at 1 year for those implanted with continuous-flow devices as DT (n=740) demonstrate that 74% are alive with a device in place, 3% transition to transplant candidacy, and 1% recover.10

Park and colleagues11 performed an observational investigation in 281 patients who underwent continuous-flow LVAD placement for DT from May 2007 to March 2009 and compared this cohort with an early group of 133 continuous-flow LVAD patients from March 2005 to May 2007. Patient entry criteria were the same during the 2 time periods. The more recent group had reduced adverse event rates for bleeding requiring transfusions (1.66 versus 1.13 events per patient-year; P<0.001), sepsis (0.38 versus 0.27 events per patient-year; P=0.025), device-related infections (0.47 versus 0.27 events per patient-year; P<0.001), and hemorrhagic stroke (0.07 versus 0.03 events per patient-year; P=0.01). Other event rates, including ischemic stroke (0.06 versus 0.05 events per patient-year; P=0.57), were similar between groups. Survival at 1 year in the contemporary group was 73%, similar to that reported by the aggregate INTERMACS database.

Importantly, there is evidence of durability beyond the first year, as noted by the >70% survival at 2 years in the INTERMACS database. Thus, the Continuous Access Protocol and Post Marketing real-world experience points to the consistency of a large increase in survival in the patients with as much as an absolute improvement in survival of >10% compared with the index study cohort.

These outcomes with continuous-flow LVADs are clearly better than those with medical therapy alone, exhibit durability of benefit beyond 1 year, and are sufficient to consider this therapy the standard of care for patients with advanced refractory heart failure and no option for transplantation.

Concept of Bridge to Candidacy
One of the most vexing dilemmas encountered by clinicians is the “gray zone” in which current comorbidities render a patient ineligible for cardiac transplantation but there is the possibility of sufficient physiological improvement after hemodynamic support to make the patient a transplantation candidate. With LVAD-based hemodynamic unloading, patients exhibiting pulmonary hypertension or profound hepatorenal dysfunction often demonstrate recovery of these organ systems.12,13 In the absence of reasons for permanent ineligibility for transplantation such as advanced age or complex diabetes mellitus, patients are often classified into this category of bridge to candidacy. The INTERMACS report outlines that 38% to 40.5% of all devices placed in 2010 to 2011 (first 6 months) were in this category, making this the most commonly listed indication at the time of LVAD implantation. At 1 year, 56% remained on a continuous-flow device, 26% were successfully transplanted, and 17% died.10 Figure 1 depicts the dramatic advances in survival with LVAD therapy compared with treatment for advanced heart failure. Figure 2 outlines the proportion of MCS devices placed in transplantation-ineligible patients and their clinical outcomes.

Selection of the Appropriate Patient for Lifetime MCS Therapy
Today, permanently (DT) or currently (bridge to candidacy) transplantation-ineligible patients form the dominant indication groups for durable lifetime MCS in the United States.
Although the rate of MCS as a bridge to transplantation has not changed, 75% of all permanent MCS implantations in the US are now in the non–transplantation-eligible population at the time of decision. However, as this population of advanced heart failure patients continues to grow, the appropriate use of lifetime MCS will become an important decision as a standard of care. In this regard, it is vital that clinicians develop decision rules that allow them to select patients appropriately. A critical problem encountered early in the course of application of this therapy was the use in patients who were “crashing and burning,” those in cardiogenic shock. Such patients were uniformly less likely to benefit from MCS than more stable patients (INTERMACS 2 and 3 as opposed to INTERMACS 1). Similarly, the use of LVADs in “less sick” (INTERMACS 5 and above) patients is also not supported at this time. Although the HeartMate II trial enrolled New York Heart Association class IIIB patients, current data do not provide sufficient justification for use of permanent MCS in these patients. Such patients are difficult to classify, and although those enrolled in the clinical trials were often on chronic inotropic support, this treatment is not well supported for ambulatory non–inotropic therapy–bound patients with advanced heart failure. Increasing survival and improving outcomes with the current generation of continuous-flow devices have led to sufficient equipoise that the National Heart, Lung, and Blood Institute has supported the Randomized Evaluation of VAD Intervention Before Inotropic Therapy (REVIVE-IT) study to investigate the feasibility and usefulness in ambulatory advanced heart failure patients who have not yet reached the point of inotropic support. We believe that the best outcomes will be achieved by appropriate referral of patients to specialized centers. There is evidence that centers with well-coordinated MCS teams that provide comprehensive care achieve the best outcomes. To avoid the poor results caused by preimplantation organ dysfunction, referral to an MCS center should be contemplated early. Clinicians must change their mindset typically from one focused solely on symptom-directed management to one that amplifies prognosis as a vital consideration, even when reasonable temporary symptom control is manifest. Thus, simple algorithms that facilitate early referral to specialized centers that offer team-based advanced therapy should be used (Figure 3). Continued uncertainty surrounds the need for concurrent right ventricular support in the setting of the need for an LVAD. Several algorithms exist to distinguish patients likely to require biventricular support, and this aspect is of critical importance because of the lack of optimal outcomes, especially in the setting of transplantation-ineligible patients.

**Economic Considerations**

The use of LVADs is extraordinarily expensive and occurs in an era of great fiscal stress. In a recent analysis of MCS in DT indications, Rogers and colleagues constructed a Markov model to assess cost-effectiveness. Survival, hospitalization rates, quality of life, and cost data were obtained for advanced heart failure patients treated medically or with a continuous-flow LVAD. They demonstrated that compared with medically managed patients, the incremental cost-effectiveness ratio of the continuous-flow device was $198,184 per quality-adjusted life-year and $167,208 per life-year. Thus, the technology continues to be more expensive than the conventionally accepted incremental cost-effectiveness ratio threshold of $50,000 derived from data using chronic renal replacement therapy. However, medical expendi-
Tures are not a “zero sum” game in the strict sense of that term, and decisions about what resources should be allotted to advanced heart failure and to LVADs are societal decisions that occur within the context of consideration of both medical and nonmedical priorities, which is beyond the scope of this discussion.

The Future of MCS in Transplantation-Ineligible Advanced Heart Failure

Improved Device Technology
Continued improvements in MCS systems are occurring and are likely to broaden the indications for implantation. Smaller devices are being developed. Systems that can be completely implanted would be a major advancement by reducing infection risk and improving the quality of patients’ lives. MCS that uses a wireless energy transfer will reduce the high risk of driveline infections and provide greater mobility and thus better quality of life for patients. Ultimately, a practical total cardiac replacement that is fully implantable, highly reliable, and responsive to changing patient cardiac output needs would complete the evolution.22 Perhaps the greatest challenge that remains of concern is in neurological outcomes with current MCS devices, a morbidity that has not improved despite the advent of newer devices. This requires further study.23

Alternatives to MCS
Heart failure represents the final common pathway of a number of diseases and will continue, despite advances in intervention, to be a major cause of disability and death with a large number of such patients transitioning to advanced heart failure syndromes.24 The size of the donor pool will not increase sufficiently to make allogeneic transplantation more than of limited public health significance.25 In fact, there has been no increase in the number of organ donors in the past decade; therefore, heart transplantation is never likely to offer
a widespread solution for the continually increasing number of patients with advanced heart failure. Crossing the HLA barrier and allowing xenotransplantation is a distant goal, and stem cell–based cardiac regeneration remains in its infancy, although its apparent potential is exciting. It is conceivable that combining cell-based therapy with MCS devices may offer incremental hope for potential myocardial recovery, a concept under scrutiny as part of the Clinical Cell Trial Research Network, funded by the National Heart, Lung, and Blood Institute.

Thus, in the foreseeable future, advances in MCS will form the backbone of the standard of care in appropriately selected patients with advanced refractory heart failure.

Disclosures

Dr Mehra serves as chairman of the Data and Safety Monitoring Board for the REVIVE-IT Study, funded by the National Heart, Lung, and Blood Institute. In addition, he reports consulting income from St. Jude’s, Medtronic, Abbott Vascular, Johnson & Johnson, and the American Board of Internal Medicine. Dr Domanski reports consulting income from CardioMems.

References


We appreciate Drs Mehra and Domanski’s overview of the history and evolution of left ventricular assist devices. We agree that newer-generation devices have demonstrated increased durability compared with first-generation pulsatile devices and that purely medical management of advanced heart failure has remained disappointingly stagnant. However, as acknowledged by the authors themselves, mechanical circulatory support is successful only in “well-selected patients with refractory heart failure,” which is a far cry from stating that mechanical circulatory support is a substitute in all patients who are not eligible for heart transplantation. They further acknowledge the critical importance of distinguishing which patients have a need for permanent biventricular support, which is not feasible with current mechanical circulatory support device technology and Food and Drug Administration regulations. They outline the limited survival data for destination therapy patients, available in the latest Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) report, and the high societal cost of this therapy. Furthermore, they acknowledge the continued, unimproved rate of neurological complications with newer-generation left ventricular assist devices. In conclusion, although Drs Mehra and Domanski provide an accurate historical picture of the mechanical circulatory support landscape and an optimistic outlook for future advances, they do not provide convincing evidence that left ventricular assist devices should be standard of care for transplantation-ineligible patients. Heart failure is primarily a disease of elderly patients with multiple comorbidities; the majority of patients with heart failure would not be well served by either transplantation or left ventricular assist device implantation, but a renewed focus on quality of life.
Should Left Ventricular Assist Device Should Be Standard of Care for Patients With Refractory Heart Failure Who Are Not Transplantation Candidates?: Left Ventricular Assist Devices Should Be Considered Standard of Care for Patients With Refractory Heart Failure Who Are Not Transplantation Candidates

Mandeep R. Mehra and Michael J. Domanski

Circulation. 2012;126:3081-3087
doi: 10.1161/CIRCULATIONAHA.111.079301

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/126/25/3081

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation is online at:
http://circ.ahajournals.org/subscriptions/